Serum untargeted metabolomic changes in response to diet intervention in dogs with preclinical myxomatous mitral valve disease
暂无分享,去创建一个
[1] P. E. Verkade,et al. Researches on fat metabolism. II. , 1934, The Biochemical journal.
[2] F. Kunz,et al. Plasma phosphatidylethanolamine--a better indicator in the predictability of atherosclerotic complications? , 1971, Atherosclerosis.
[3] A. Bach,et al. Effect of the Fatty Acid Composition of Ingested Fats on Rat Liver Intermediary Metabolism , 1976, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[4] A. Bach,et al. Ketogenic response to medium-chain triglyceride load in the rat. , 1977, The Journal of nutrition.
[5] A. Bach,et al. Medium-chain triglycerides: an update. , 1982, The American journal of clinical nutrition.
[6] L. Sartorelli,et al. On the transport mechanisms of carnitine and its derivative in rat heart slices. , 1982, The Italian journal of biochemistry.
[7] R. Gross. Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum. , 1985, Biochemistry.
[8] H. Kaunitz. Medium chain triglycerides (MCT) in aging and arteriosclerosis. , 1986, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[9] L. Sartorelli,et al. Myocardial carnitine transport. , 1987, Basic research in cardiology.
[10] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[11] P. J. Jones,et al. Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. , 1998, Life sciences.
[12] H. Pedersen,et al. Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. , 2000, Cardiovascular research.
[13] C. Colton,et al. Mechanisms of the antioxidant effects of nitric oxide. , 2001, Antioxidants & redox signaling.
[14] R. Wanders,et al. Carnitine biosynthesis in mammals. , 2002, The Biochemical journal.
[15] A. Simopoulos,et al. The importance of the ratio of omega-6/omega-3 essential fatty acids. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[16] C. Roe,et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. , 2002, The Journal of clinical investigation.
[17] Douglas M. Hawkins,et al. A variance-stabilizing transformation for gene-expression microarray data , 2002, ISMB.
[18] J. Blumberg,et al. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. , 2005, Journal of veterinary internal medicine.
[19] K. Naseem. The role of nitric oxide in cardiovascular diseases. , 2005, Molecular aspects of medicine.
[20] D. Matern,et al. Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management , 2005, Pediatric Research.
[21] T. Lüscher,et al. Nitric Oxide in Hypertension , 2006, Journal of clinical hypertension.
[22] R. A. van den Berg,et al. Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.
[23] S. Chittur,et al. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. , 2006, American journal of veterinary research.
[24] Stefan Neubauer,et al. The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.
[25] B. Fielding,et al. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. , 2008, Progress in lipid research.
[26] C. Des Rosiers,et al. Medium-chain Fatty Acids as Metabolic Therapy in Cardiac Disease , 2008, Cardiovascular Drugs and Therapy.
[27] A. Simopoulos,et al. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases , 2008, Experimental biology and medicine.
[28] C. Hoppel,et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. , 2009, The Journal of nutrition.
[29] A. Lochner,et al. Nitric oxide in the cardiovascular system: a simple molecule with complex actions , 2009, Cardiovascular journal of Africa.
[30] L. Freeman. Beneficial effects of omega-3 fatty acids in cardiovascular disease. , 2010, The Journal of small animal practice.
[31] R. Wanders,et al. Fatty acid omega‐oxidation as a rescue pathway for fatty acid oxidation disorders in humans , 2011, The FEBS journal.
[32] F. Recchia,et al. Modulating fatty acid oxidation in heart failure. , 2011, Cardiovascular research.
[33] W. Kraus,et al. Metabolic profiles predict adverse events after coronary artery bypass grafting. , 2012, The Journal of thoracic and cardiovascular surgery.
[34] A. Abdel-Naim,et al. Anti-inflammatory activity of methyl palmitate and ethyl palmitate in different experimental rat models. , 2012, Toxicology and applied pharmacology.
[35] William E. Kraus,et al. Metabolomic Profiling for the Identification of Novel Biomarkers and Mechanisms Related to Common Cardiovascular Diseases: Form and Function , 2012, Circulation.
[36] E. Riboli,et al. Plasma Phospholipid Fatty Acid Concentration and Incident Coronary Heart Disease in Men and Women: The EPIC-Norfolk Prospective Study , 2012, PLoS medicine.
[37] Torsten Doenst,et al. Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production , 2013, Circulation research.
[38] Stephen T. C. Wong,et al. Mechanical Unloading Promotes Myocardial Energy Recovery in Human Heart Failure , 2014, Circulation. Cardiovascular genetics.
[39] M. Kuzuya,et al. Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. , 2014, Biochemical and Biophysical Research Communications - BBRC.
[40] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[41] Rick B. Vega,et al. Energy Metabolic Reprogramming in the Hypertrophied and Early Stage Failing Heart: A Multisystems Approach , 2014, Circulation. Heart failure.
[42] M. Schulze,et al. Association between erythrocyte membrane fatty acids and biomarkers of dyslipidemia in the EPIC-Potsdam study , 2014, European Journal of Clinical Nutrition.
[43] D. Argyle,et al. Gene network and canonical pathway analysis in canine myxomatous mitral valve disease: a microarray study. , 2015, Veterinary journal.
[44] Rick B. Vega,et al. Mitochondrial biogenesis and dynamics in the developing and diseased heart , 2015, Genes & development.
[45] David S. Wishart,et al. MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..
[46] S. Hannah,et al. Veterinary Medicine and Multi-Omics Research for Future Nutrition Targets: Metabolomics and Transcriptomics of the Common Degenerative Mitral Valve Disease in Dogs. , 2015, Omics : a journal of integrative biology.
[47] A. Koulman,et al. A Review of Odd-Chain Fatty Acid Metabolism and the Role of Pentadecanoic Acid (C15:0) and Heptadecanoic Acid (C17:0) in Health and Disease , 2015, Molecules.
[48] Rick B. Vega,et al. The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.
[49] K. Margulies,et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.
[50] D. El-Agamy,et al. Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate , 2017, Cancer Chemotherapy and Pharmacology.
[51] K. Hirata,et al. 2-Aminobutyric acid modulates glutathione homeostasis in the myocardium , 2016, Scientific Reports.
[52] J. Zavadil,et al. Mitral valve prolapse is associated with altered extracellular matrix gene expression patterns. , 2016, Gene.
[53] V. Macrae,et al. Comparative Transcriptomic Profiling and Gene Expression for Myxomatous Mitral Valve Disease in the Dog and Human , 2017, Veterinary sciences.
[54] Ismael Saifudeen,et al. Metabolic Modulation by Medium-Chain Triglycerides Reduces Oxidative Stress and Ameliorates CD36-Mediated Cardiac Remodeling in Spontaneously Hypertensive Rat in the Initial and Established Stages of Hypertrophy. , 2017, Journal of cardiac failure.
[55] Öztun Temelli,et al. Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience. , 2017, The Gulf journal of oncology.
[56] Y. Pinto,et al. Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. , 2017, JACC. Heart failure.
[57] D. Mozaffarian,et al. Circulating Very Long‐Chain Saturated Fatty Acids and Heart Failure: The Cardiovascular Health Study , 2018, Journal of the American Heart Association.
[58] Scott B. Crown,et al. Cardiovascular Metabolomics , 2018, Circulation research.
[59] Jung-Wan Kim,et al. An evidence of C16 fatty acid methyl esters extracted from microalga for effective antimicrobial and antioxidant property. , 2018, Microbial pathogenesis.
[60] R. Vasan,et al. Ceramide Remodeling and Risk of Cardiovascular Events and Mortality , 2018, Journal of the American Heart Association.
[61] D. Priolli,et al. Plasmalogen lipids: functional mechanism and their involvement in gastrointestinal cancer , 2018, Lipids in Health and Disease.
[62] Qinghong Li,et al. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs , 2019, BMC veterinary research.
[63] D. Mozaffarian,et al. Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk. , 2019, Circulation. Heart failure.
[64] Jing Wang,et al. Disturbed energy and amino acid metabolism with their diagnostic potential in mitral valve disease revealed by untargeted plasma metabolic profiling , 2019, Metabolomics.
[65] R. Levy,et al. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms. , 2020, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[66] Jacob E. Wulff,et al. Precision of a Clinical Metabolomics Profiling Platform for Use in the Identification of Inborn Errors of Metabolism. , 2020, The journal of applied laboratory medicine.